HistoGenetics Selects Illumina, Inc. (ILMN)'s MiSeq® System as Next-Generation Sequencing Platform of Choice
7/22/2013 9:59:25 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that HistoGenetics, the leader in high-resolution sequence-based human leukocyte antigen (HLA) testing services, has selected the MiSeq sequencing system for use in its CLIA laboratory. HistoGenetics will deploy multiple MiSeqs to supplement its existing Sanger sequencing workflow to sequence HLA genes with high accuracy and speed. In addition to their utility in tissue matching for transplants, HLA gene variations have known associations with a wide variety of autoimmune diseases, infectious diseases, and some cancers.
Help employers find you! Check out all the jobs and post your resume.